Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third time's the charm for $100 million Merrimack IPO after two false starts

This article was originally published in Scrip

Executive Summary

After a false start earlier this year, Cambridge, Massachusetts-based Merrimack Pharmaceuticals Inc. launched on the Nasdaq with an initial public offering of 14.3 million shares of common stock priced at $7 per share to raise $100.1 million on 29 March.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016803

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel